Cancer Medicine
Open Access
ORIGINAL RESEARCH
The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution Lauren Bonomo1, Jerry Lue1, Sundar Jagannath2 & Ajai Chari2 1Department 2Division
of Medical Education, Icahn School of Medicine at Mount Sinai, New York City, New York 10029 of Hematology Oncology, Icahn School of Medicine at Mount Sinai, Gustave Levy Place, Box 1185, New York City, New York 10029
Keywords Chemotherapy, elderly, myeloma, neoplasms, plasma cell, United States Correspondence Ajai Chari, MD, Department of Medicine, Division of Hematology Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029. Tel: 212-241-7873; Fax: 212-241-3908: E-mail: [email protected] Funding Information We thank Patricia S. Levinson for providing the funding for LB and JL to complete this research. Received: 15 July 2015; Revised: 19 October 2015; Accepted: 24 November 2015 Cancer Medicine 2016; 5(3):500–505 doi: 10.1002/cam4.620
Abstract Improvements in the outcomes of elderly multiple myeloma (MM) patients have lagged behind those of transplant-eligible patients, likely due in part to the use of less efficacious melphalan-containing regimens. To date, there are very limited data for the outcomes of elderly MM patients in the United States (US), particularly for novel agent-containing triplet regimens. In this retrospective study at a single U.S. institution, the outcomes of 117 consecutive newly diagnosed, symptomatic MM patients over the age of 70 were evaluated. The median age was 75 years (range 70–95) with significant baseline comorbidities including 36% cardiac and 20% renal (CrCl
Open Access
ORIGINAL RESEARCH
The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution Lauren Bonomo1, Jerry Lue1, Sundar Jagannath2 & Ajai Chari2 1Department 2Division
of Medical Education, Icahn School of Medicine at Mount Sinai, New York City, New York 10029 of Hematology Oncology, Icahn School of Medicine at Mount Sinai, Gustave Levy Place, Box 1185, New York City, New York 10029
Keywords Chemotherapy, elderly, myeloma, neoplasms, plasma cell, United States Correspondence Ajai Chari, MD, Department of Medicine, Division of Hematology Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029. Tel: 212-241-7873; Fax: 212-241-3908: E-mail: [email protected] Funding Information We thank Patricia S. Levinson for providing the funding for LB and JL to complete this research. Received: 15 July 2015; Revised: 19 October 2015; Accepted: 24 November 2015 Cancer Medicine 2016; 5(3):500–505 doi: 10.1002/cam4.620
Abstract Improvements in the outcomes of elderly multiple myeloma (MM) patients have lagged behind those of transplant-eligible patients, likely due in part to the use of less efficacious melphalan-containing regimens. To date, there are very limited data for the outcomes of elderly MM patients in the United States (US), particularly for novel agent-containing triplet regimens. In this retrospective study at a single U.S. institution, the outcomes of 117 consecutive newly diagnosed, symptomatic MM patients over the age of 70 were evaluated. The median age was 75 years (range 70–95) with significant baseline comorbidities including 36% cardiac and 20% renal (CrCl
